Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
August 09, 2024 17:59 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
July 24, 2024 06:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
July 11, 2024 07:15 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
July 11, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
July 03, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
July 01, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes

SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
June 25, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye BioScience Participating in Piper Sandler Virtual Obesity Day

SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 10, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

SBI-100 Ophthalmic Emulsion Phase 2a trial does not achieve target product profile; program discontinued Phase 2 study of Nimacimab in obesity expected to start in Q3 2024 Cash runway extended into...
June 03, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at Jefferies Global Healthcare Conference

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...